Ombitasvir/ Paritaprevir / Ritonavir Plus Ribavirin in Management HCV and End-stage Kidney Disease
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 110 participants.
Also called NCT03499639
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 110 participants
- Registry
-
NCT03499639
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Egypt
- Registry status
- Completed
Technical summary
Registry record NCT03499639. Allocation not applicable; no masking; primary purpose treatment. Start 2018-05-01 (actual); primary completion 2018-08-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Ombitasvir/ Paritaprevir / Ritonavir Plus Ribavirin in Management HCV and End-stage Kidney Disease
- Condition
- End-stage Renal Disease
- Condition
- HCV Coinfection
- Intervention (Drug)
- Ombitasvir / Paritaprevir / Ritonavir /Ribavirin Oral Tablet
- Lead sponsor
- Assiut University
- Collaborator
- Sohag University
- Collaborator
- South Valley University
Record details
- Record id
cardio:ct-nct03499639- Content hash
22499048e5395b47af94661ba4d2b5b76c106377c57203d33aaa8dc0678e7e5d